← Back to Search

Ultrasound Therapy

ExAblate BBB Disruption for Alzheimer's Disease

N/A
Recruiting
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or Female between 50-85 years of age
Probable Alzheimer's Disease (AD)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial is testing a new tool to see if it can help patients with Alzheimer's by disrupting the blood-brain barrier.

Who is the study for?
This trial is for people aged 50-85 with probable Alzheimer's Disease who can walk and report sensations during the procedure. They must have been on stable Alzheimer's medication for at least 3 months if applicable. Exclusions include significant heart disease, MRI contraindications, bleeding disorders, severe liver or kidney issues, untreated sleep apnea, seizure history, current participation in other trials, chronic lung problems, HIV positive status or certain genetic risk factors.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of the ExAblate Model 4000 Type 2.0 System to temporarily disrupt the blood-brain barrier in patients with Alzheimer's Disease. This disruption could potentially allow better delivery of treatments to the brain.See study design
What are the potential side effects?
Potential side effects may include discomfort from wearing a head frame during treatment and risks associated with MRI procedures such as reactions to contrast agents used during scanning.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 85 years old.
Select...
I have been diagnosed with probable Alzheimer's Disease.
Select...
I can walk on my own without help.
Select...
I am between 50 and 85 years old.
Select...
I have been diagnosed with probable Alzheimer's Disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Device and procedure related adverse events
Other outcome measures
BBB Disruption and Closure

Trial Design

1Treatment groups
Experimental Treatment
Group I: Blood Brain Barrier (BBB) DisruptionExperimental Treatment1 Intervention
ExAblate Model 4000 Type 2.0 System

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
89 Previous Clinical Trials
3,564 Total Patients Enrolled

Media Library

ExAblate Model 4000 Type 2.0 System (Ultrasound Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03671889 — N/A
Alzheimer's Disease Research Study Groups: Blood Brain Barrier (BBB) Disruption
Alzheimer's Disease Clinical Trial 2023: ExAblate Model 4000 Type 2.0 System Highlights & Side Effects. Trial Name: NCT03671889 — N/A
ExAblate Model 4000 Type 2.0 System (Ultrasound Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03671889 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants has this research recruited thus far?

"This research project requires 30 qualified participants. Those eligible to take part can do so from various authorised sites, such as Broward Health Medical Center in Fort Lauderdale, Texas and Baptist Health South Florida in Miami, New york."

Answered by AI

Are there any openings left for participants in this research project?

"Affirmative, the clinicaltrials.gov portal reflects that this trial is recruiting participants; it was initially posted on September 28th 2018 and recently revised on July 11th 2022. The study seeks to enrol 30 patients at 9 different sites."

Answered by AI

Are participants of advanced age eligible for this research study?

"The parameters for this evaluation stipulate that only those aged 50-85 can be admitted."

Answered by AI

What is the extent of geographical participation for this research endeavor?

"Nine medical centres are currently participating in this investigation, including Broward Health Medical Center in Fort Lauderdale and Baptist Health South Florida in Miami. Additionally, University of Texas Southwestern Medical Center located Dallas is also included among the 9 study sites."

Answered by AI

What is the criteria for enrollment in this clinical experiment?

"This research is looking for 30 individuals with Alzheimer's disease, aged between 50 and 85. To be eligible applicants must demonstrate the capacity to communicate during the ExAblate MRgFUS process, have been on a stable dosage of their prescribed medication for at least two months (if applicable), identify as male or female, display symptoms consistent with probable AD, and possess basic ambulatory skills."

Answered by AI

Who else is applying?

What state do they live in?
New York
What site did they apply to?
Weill Cornell Medicine
University of Texas Southwestern Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
1
0

What questions have other patients asked about this trial?

How long does screening take?
PatientReceived no prior treatments

Why did patients apply to this trial?

Only one drug has ever been prescribed.
PatientReceived 1 prior treatment
~14 spots leftby Dec 2024